Table 1.
Patient demographics, clinical and lesion characteristics in 90 patients with 99 high-risk lesions detected on MRI-VAB
| Characteristic | |
| Median age (range), yrs | 53 (28–79) |
| Race/ethnicity | |
| White | 71 (71) |
| Black | 10 (10) |
| Hispanic | 13 (13) |
| Asian | 3 (3) |
| Unspecified | 2 (2) |
| Indications for diagnostic breast MRI | |
| Screening | 25 (25) |
| Work-up of unresolved imaging findings | 12 (12) |
| Known breast cancer | 42 (42) |
| Ipsilateral breast cancer | 22 (22) |
| Contralateral breast cancer | 20 (20) |
| Assessment of residual cancer after surgical excision | 3 (3) |
| Assessment of tumor response to neoadjuvant chemotherapy | 2 (2) |
| Axillary metastasis with unknown primary tumor | 1 (1) |
| History of breast cancer | 1 (1) |
| Othera | 13 (13) |
| Lesion characteristics | |
| Non-mass enhancement | 54 (54) |
| Mass | 39 (39) |
| Focus | 6 (6) |
| Contrast enhancement kinetics | |
| Washout | 32 (32) |
| Persistent | 39 (39) |
| Plateau | 25 (25) |
| Unavailable | 3 (3) |
| Number of samples taken on MRI-VAB, median (range) | 12 (4−22) |
| VAB histopathology | |
| ADH | 21 (21) |
| Lobular neoplasia | 36 (36) |
| ALH | 22 (22) |
| LCIS | 6 (6) |
| Both ALH and LCIS | 8 (8) |
| Papillary lesion | 22 (22) |
| Radial scar | 11 (11) |
| Flat epithelial atypia | 1 (1) |
| Atypia unspecified | 8 (8) |
| Mucocele-like lesion | 0 (0) |
ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; LCIS, lobular carcinoma in situ; MRI-VAB, MRI-vacuum-assisted biopsy.
Numbers in parentheses are percentages.
a
Other refers to skin thickening, nipple discharge and palpable findings.